These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12386644)

  • 21. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion.
    Sieber CC; Beglinger C; Bart S; Tschoepl M; Currie G; Larsen F; Drewe J
    Clin Pharmacol Ther; 2004 Jan; 75(1):70-9. PubMed ID: 14749693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension.
    Ostermann G; Brisgand B; Schmitt J; Fillastre JP
    Am J Cardiol; 1988 Feb; 61(7):76D-80D. PubMed ID: 2894164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose response and safety of telmisartan in patients with mild to moderate hypertension.
    Smith DH; Matzek KM; Kempthorne-Rawson J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1380-90. PubMed ID: 11185637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of rilmenidine (hyperium) on lipid balance in hyperlipidemic hypertensive patients. Randomized, controlled, double-blind 8-week study vs. captopril in parallel groups].
    Scemama M; Février B; Beucler I; Dairou F
    Ann Cardiol Angeiol (Paris); 1996 Dec; 45(10):595-601. PubMed ID: 9033699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
    Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
    J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Essential arterial hypertension treated with rilmenidin : what dose for what patient?].
    Amah G
    Presse Med; 1999 Jan; 28(1):11-6. PubMed ID: 9951504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine.
    Haller CA; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 2004 Apr; 75(4):259-73. PubMed ID: 15060505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rilmenidine--its antihypertensive efficacy, safety and impact on quality of life in perimenopausal women with mild to moderate essential hypertension.
    Kawecka-Jaszcz K; Czarnecka D; Klocek M; Zabojszcz M; Kucharska M; Jaworski R; Pachocki R
    Blood Press; 2006; 15(1):51-8. PubMed ID: 16492616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J;
    Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of rilmenidine on arterial parameters in essential arterial hypertension].
    Pannier B; Safar M
    Arch Mal Coeur Vaiss; 1989 Dec; 82 Spec No 5():47-51. PubMed ID: 2517009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The chronic effect of rilmenidine on heart rate variability in patients with mild hypertension.
    Eryonucu B; Ulgen MS; Bilge M; Güler N; Güneş A
    Angiology; 2002; 53(2):199-204. PubMed ID: 11952111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.